Medite Cancer Diagnostics Stock Net Income
| MDIT Stock | USD 0.0001 0.00 0.00% |
Medite Cancer's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Medite Pink Sheet price.
Medite |
Medite Cancer Diagnostics Company Net Income Analysis
Medite Cancer's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Medite Cancer Net Income | (6.81 M) |
Most of Medite Cancer's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medite Cancer Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Medite Cancer Diagnostics reported net income of (6.81 Million). This is 102.0% lower than that of the Health Care Equipment & Supplies sector and 106.84% lower than that of the Health Care industry. The net income for all United States stocks is 101.19% higher than that of the company.
Medite Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medite Cancer's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Medite Cancer could also be used in its relative valuation, which is a method of valuing Medite Cancer by comparing valuation metrics of similar companies.Medite Cancer is currently under evaluation in net income category among its peers.
Medite Fundamentals
| Return On Equity | -0.74 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.65) % | |||
| Operating Margin | (0.49) % | |||
| Current Valuation | 7.44 M | |||
| Shares Outstanding | 86.72 M | |||
| Price To Earning | (2.47) X | |||
| Price To Book | 0.21 X | |||
| Price To Sales | 0.11 X | |||
| Revenue | 6.81 M | |||
| Gross Profit | 162 K | |||
| EBITDA | (6.19 M) | |||
| Net Income | (6.81 M) | |||
| Cash And Equivalents | 90 K | |||
| Total Debt | 4.91 M | |||
| Debt To Equity | 0.94 % | |||
| Current Ratio | 1.11 X | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (3.57 M) | |||
| Earnings Per Share | (0.11) X | |||
| Number Of Employees | 69 | |||
| Beta | 75.45 | |||
| Market Capitalization | 520.34 K | |||
| Total Asset | 15.96 M | |||
| Retained Earnings | (351 K) | |||
| Working Capital | (1.36 M) | |||
| Current Asset | 5.95 M | |||
| Current Liabilities | 7.31 M | |||
| Net Asset | 15.96 M |
About Medite Cancer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medite Cancer Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medite Cancer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medite Cancer Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Medite Pink Sheet Analysis
When running Medite Cancer's price analysis, check to measure Medite Cancer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medite Cancer is operating at the current time. Most of Medite Cancer's value examination focuses on studying past and present price action to predict the probability of Medite Cancer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medite Cancer's price. Additionally, you may evaluate how the addition of Medite Cancer to your portfolios can decrease your overall portfolio volatility.